Susanna Gatti High Sells 8,976 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) COO Susanna Gatti High sold 8,976 shares of the stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $34.41, for a total transaction of $308,864.16. Following the completion of the transaction, the chief operating officer now owns 131,636 shares in the company, valued at $4,529,594.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Susanna Gatti High also recently made the following trade(s):

• On Friday, June 21st, Susanna Gatti High sold 29,787 shares of Dyne Therapeutics stock. The stock was sold at an average price of $35.01, for a total value of $1,042,842.87.
• On Monday, June 24th, Susanna Gatti High sold 10,163 shares of Dyne Therapeutics stock. The shares were sold at an average price of $35.33, for a total value of $359,058.79.

Dyne Therapeutics Stock Up 0.5 %

Shares of Dyne Therapeutics stock opened at $36.59 on Friday. Dyne Therapeutics, Inc. has a twelve month low of $6.40 and a twelve month high of $47.45. The business has a 50-day moving average price of $41.07 and a 200-day moving average price of $33.55. The firm has a market cap of $3.20 billion, a price-to-earnings ratio of -9.22 and a beta of 1.07.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.02. On average, equities analysts expect that Dyne Therapeutics, Inc. will post -2.96 EPS for the current fiscal year.

Analysts Set New Price Targets

DYN has been the topic of a number of analyst reports. Piper Sandler lifted their price objective on Dyne Therapeutics from $43.00 to $53.00 and gave the company an “overweight” rating in a research report on Tuesday, August 13th. JPMorgan Chase & Co. lifted their price target on shares of Dyne Therapeutics from $39.00 to $43.00 and gave the company an “overweight” rating in a report on Tuesday, July 9th. Morgan Stanley increased their price objective on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Guggenheim lifted their target price on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, August 15th. Finally, StockNews.com lowered Dyne Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 16th. One investment analyst has rated the stock with a sell rating, nine have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $51.40.

Institutional Investors Weigh In On Dyne Therapeutics

Several large investors have recently bought and sold shares of the business. RA Capital Management L.P. bought a new stake in shares of Dyne Therapeutics in the 1st quarter worth about $140,666,000. Janus Henderson Group PLC grew its position in Dyne Therapeutics by 23,512.0% in the first quarter. Janus Henderson Group PLC now owns 2,675,240 shares of the company’s stock worth $75,915,000 after acquiring an additional 2,663,910 shares in the last quarter. Frazier Life Sciences Management L.P. bought a new stake in Dyne Therapeutics during the fourth quarter worth approximately $15,758,000. Price T Rowe Associates Inc. MD raised its position in Dyne Therapeutics by 8,284.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,132,092 shares of the company’s stock valued at $32,141,000 after purchasing an additional 1,118,590 shares during the period. Finally, Vanguard Group Inc. lifted its stake in shares of Dyne Therapeutics by 47.7% in the 1st quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company’s stock valued at $97,669,000 after purchasing an additional 1,110,629 shares during the last quarter. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.